. 2023 Jan 13;43(3):421–435. doi: 10.1007/s00296-022-05270-6

Table 1.

Studies included in this SLR, which reported the difference on the HZ-incidence among patients receiving different JAKi

Author (ref), year, region	Study type	Observational period	Age, years^a	Concomitant GCs ^b % (dose^c)	Cumulative HZ-incidence, % (n/N)	p-value	RoB
Miyazaki [59] 2021, Japan	Cohort	24 weeks	59.1 (13.4)	TOFA^: 16% (5.0) BARI^: 17% (7.5)	1.3^¥ (2/156)	3.6^¥¥ (5/138)	0.18	Intermediate
Iwamoto [58] 2021, Japan	Cohort	24 weeks	66.5 (12.2)	TOFA^: 53% (4.8) BARI^: 47% (4.8)	5.6^§ (9/161)	4.9^§§ (4/81)	NR^¶	Intermediate

Author (ref), year, region

Study type

Observational period

Age, years^a

Concomitant GCs ^b % (dose^c)

Cumulative HZ-incidence, % (n/N)

p-value

RoB

TOFA

BARI

Miyazaki [59]

2021, Japan

Cohort

24 weeks

59.1 (13.4)

TOFA^*: 16% (5.0)

BARI^*: 17% (7.5)

1.3^¥ (2/156)

3.6^¥¥ (5/138)

0.18

Intermediate

Iwamoto [58]

2021, Japan

Cohort

24 weeks

66.5 (12.2)

TOFA^*: 53% (4.8)

BARI^*: 47% (4.8)

5.6^§

(9/161)

4.9^§§

(4/81)

NR^¶

Intermediate

^aMean/median (SD/IQR)

^bReported at baseline

^cMean daily dose (mg)

^*Non-significant difference of concomitant GC use between TOFA and BARI groups

^¥ 89.7% received 10 mg and 10.3% received 5 mg BID

^¥¥ 88.4% received 4 mg and 11.6% 2 mg QD

^§All received 5 mg BID

^§^§All received 4 mg QD

^¶ Not reported. The authors only mentioned that the difference was non-significant

GCs glucocorticoids, HZ herpes zoster, RoB risk of bias, TOFA tofacitinib, BARI baricitinib